Postpartum hemorrhage (PPH) is a potentially fatal complication of vaginal and cesarean deliveries. The active management of the third stage of labor provides administration of prophylactic uterotonic drugs just before or immediately after delivery, since they reduce the risk of PPH by 60%.
Objective:
Overview on all available uterotonics for PPH prevention to clarify indications and contraindications in choice among drugs.
Search Strategy:
Systematic review of the literature.
Main Results:
Oxytocin is the first choice for PPH prophylaxis. Ergot alkaloids, syntometrine, and prostaglandins are second-line uterotonic agents. Misoprostol is not effective as oxytocin but it may be used when the latter is not available. Carbetocin should be used instead of continuous oxytocin infusion in elective cesarean sections for PPH prevention and to decrease the need for therapeutic uterotonics.
Conclusions:
Prophylactic oxytocics should be offered routinely in the third stage of labor in all women. The prophylactic use of uterotonics should be individualized.
World Health Organization. Recommendations for the Prevention of Postpartum Haemorrhage.
2.
LeducDSenikasVLalondeAB. Clinical Practice Obstetrics Committee; Society of Obstetricians and Gynaecologists of Canada. Active management of the third stage of labour: prevention and treatment of postpartum hemorrhage. J Obstet Gynaecol Can. 2009;31(10):980–993.
3.
CarroliGCuestaCAbalosEGulmezogluAM. Epidemiology of postpartum haemorrhage: a systematic review. Best Pract Res Clin Obstet Gynaecol. 2008;22(6):999–1012.
4.
BegleyCMGyteGMDevaneDMcGuireWWeeksA.Active versus expectant management for women in the third stage of labour. Cochrane Database Syst Rev. 2011;(11): CD007412.
5.
ThomasJCallwoodAParanjothyS. National Sentinel Caesarean Section Audit: update. Pract Midwife. 2000;3(11):20.
6.
OladapoOTFawoleBBlumJAbalosE.Advance misoprostol distribution for preventing and treating postpartum haemorrhage. Cochrane Database Syst Rev. 2012;2:CD009336.
7.
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 76, October 2006: postpartum hemorrhage. Obstet Gynecol. 2006;108(4):1039–1047.
8.
JansenAJvan RhenenDJSteegersEADuvekotJJ. Postpartum hemorrhage and transfusion of blood and blood components. Obstet Gynecol Surv. 2005;60(10):663–671.
9.
CombsCAMurphyELLarosRKJr. Factors associated with postpartum hemorrhage with vaginal birth. Obstet Gynecol. 1991;77(1):69–76.
10.
PrendivilleWElbourneDChalmersI. The effects of routine oxytocic administration in the management of the third stage of labour: an overview of the evidence from controlled trials. Br J Obstet Gynaecol. 1988;95(1):3–16.
11.
OladapoOTAkinolaOIFawoleAO. Nigerian AMTSL Group. Active management of third stage of labor: evidence versus practice. Acta Obstet Gynecol Scand. 2009;88(11):1252–1260.
12.
ChongYSSuLLArulkumaranS. Current strategies for the prevention of postpartum haemorrhage in the third stage of labour. Curr Opin Obstet Gynecol. 2004;16(2):143–150.
13.
CotterAMNessATolosaJE.Prophylactic oxytocin for the third stage of labor. Cochrane Database Syst Rev. 2010; 2:CD001808.
14.
LiabsuetrakulTChoobunTPeeyananjarassriKIslamQM.Prophylactic use of ergot alkaloids in the third stage of labour. Cochrane Database Syst Rev. 2007;(2):CD005456.
15.
GülmezogluAMFornaFVillarJHofmeyrGJ.Prostaglandins for prevention of postpartum haemorrhage. Cochrane Database Syst Rev. 2004;(1):CD000494. Review. Update in: Cochrane Database Syst Rev. 2007;(3):CD000494.
NICE updates guidance on caesareans. Pract Midwife. 2011;14(11):6.
18.
DyerRAvan DykDDresnerA. The use of uterotonic drugs during caesarean section. Int J Obstet Anesth. 2010;19(3):313–319.
19.
SharmaSEl-RefaeyH. Prostaglandins in the prevention and management of postpartum haemorrhage. Best Pract Res Clin Obstet Gynaecol. 2003;17(5):811–823.
20.
RashidMClarkARashidMH.A randomised controlled trial comparing the efficacy of intramuscular syntometrine and intravenous syntocinon, in preventing postpartum haemorrhage. J Obstet Gynaecol. 2009;29(5):396–401.
21.
ZinggHHLaporteSA. The oxytocin receptor. Trends Endocrinol Metab. 2003;14(5):222–227.
22.
IvellRKimuraTMüllerD. The structure and regulation of the oxytocin receptor. Exp Physiol. 2001;86(2):289–296.
23.
GimplGFahrenholzF. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001;81(2):629–683.
24.
AriasF. Pharmacology of oxytocin and prostaglandins. Clin Obstet Gynecol. 2000;43(3):455–468.
25.
PetersNCDuvekotJJ. Carbetocin for the prevention of postpartum hemorrhage: a systematic review. Obstet Gynecol Surv. 2009;64(2):129–135.
26.
EngstrømTBarthTMelinPVilhardtH. Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation. Eur J Pharmacol. 1998;355(2-3):203–210.
27.
RathW. Prevention of postpartum haemorrhage with the oxytocin analogue carbetocin. Eur J Obstet Gynecol Reprod Biol. 2009;147(1):15–20.
28.
McDonaldSJPrendivilleWJBlairE. Randomised controlled trial of oxytocin alone versus oxytocin and ergometrine in active management of third stage of labour. BMJ. 1993;307(6913):1167–1171.
29.
van DongenPWVerbruggenMMde GrootANvan RoosmalenJSporkenJMSchulzM. Ascending dose tolerance study of intramuscular carbetocin administered after normal vaginal birth. Eur J Obstet Gynecol Reprod Biol. 1998;77(2):181–187.
30.
McDonaldSAbbottJMHigginsSP.Prophylactic ergometrine-oxytocin versus oxytocin for the third stage of labour. Cochrane Database Syst Rev. 2004;(1):CD000201.
31.
WalleyRLWilsonJBCraneJMMatthewsKSawyerEHutchensD. A double-blind placebo controlled randomised trial of misoprostol and oxytocin in the management of the third stage of labour. BJOG. 2000;107(9):1111–1115.
32.
OboroVOTaboweiTO. A randomised controlled trial of misoprostol versus oxytocin in the active management of the third stage of labour. J Obstet Gynaecol. 2003;23(1):13–16.
33.
AttilakosGPsaroudakisDAshJ. Carbetocin versus oxytocin for the prevention of postpartum haemorrhage following caesarean section: the results of a double-blind randomised trial. BJOG. 2010;117(8):929–936.
34.
BorrutoFTreisserAComparettoC. Utilization of carbetocin for prevention of postpartum hemorrhage after cesarean section: a randomized clinical trial. Arch Gynecol Obstet. 2009;280(5):707–712.
35.
HigginsLMecheryJTomlinsonAJ. Does carbetocin for prevention of postpartum haemorrhage at caesarean section provide clinical or financial benefit compared with oxytocin?J Obstet Gynaecol. 2011;31(8):732–739.
36.
SinghGRadhakrishnanGGuleriaK. Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. Int J Gynaecol Obstet. 2009;107(2):130–134.
37.
ChaudhuriPBiswasJMandalA. Sublingual misoprostol versus intramuscular oxytocin for prevention of postpartum hemorrhage in low-risk women. Int J Gynaecol Obstet. 2012;116(2):138–142.
38.
MoertlMGFriedrichSKraschlJWadsackCLangUSchlembachD. Haemodynamic effects of carbetocin and oxytocin given as intravenous bolus on women undergoing caesarean delivery: a randomised trial. BJOG. 2011;118(11):1349–1356.
39.
De BonisMTorricelliMLeoniL. Carbetocin versus oxytocin after caesarean section: similar efficacy but reduced pain perception in women with high risk of postpartum haemorrhage. J Matern Fetal Neonatal Med. 2012;25(6):732–735.
40.
FawoleAOSotiloyeOSHunyinboKI. A double-blind, randomized, placebo-controlled trial of misoprostol and routine uterotonics for the prevention of postpartum hemorrhage. Int J Gynaecol Obstet. 2011;112(2):107–111.
41.
BoltonTJRandallKYentisSM. Effect of the confidential enquiries into maternal deaths on the use of syntocinon at caesarean section in the UK. Anaesthesia. 2003;58(3):277–279.
42.
LangenbachC. Misoprostol in preventing postpartum hemorrhage: a meta-analysis. Int J Gynaecol Obstet. 2006;92(1):10–18.
43.
HofmeyrGJGülmezogluAM. Misoprostol for the prevention and treatment of postpartum haemorrhage. Best Pract Res Clin Obstet Gynaecol. 2008;22(6):1025–1041.
44.
GülmezogluAMVillarJNgocNT. WHO Collaborative Group To Evaluate Misoprostol in the Management of the Third Stage of Labour. WHO multicentre randomised trial of misoprostol in the management of the third stage of labour. Lancet. 2001;358(9283):689–695.
45.
Office of Health, Infectious Diseases and Nutrition, Bureau for Global Health, US Agency for International Development Fact sheets: Uterotonic drugs for the prevention and treatment of postpartum hemorrhage. Seattle: PATH; 2008. http://www.path.org/publications/files/MCHN_popphi_pph_fs_uterotonic.pdf.
46.
YuenPMChanNSYimSFChangAM. A randomised double blind comparison of Syntometrine and Syntocinon in the management of the third stage of labour. Br J Obstet Gynaecol. 1995;102(5):377–380.
47.
VillarJGülmezogluAMHofmeyrGJFornaF. Systematic review of randomized controlled trials of misoprostol to prevent postpartum hemorrhage. Obstet Gynecol. 2002;100(6):1301–1312.
48.
HarberCRLevyDMChidambaramSMacphersonMB.Life-threatening bronchospasm after intramuscular carboprost for postpartum haemorrhage. BJOG. 200;114(3):366–368.
49.
Royal College of Obstetricians and Gynaecologists. Prevention and management of postpartum haemorrhage. RCOG Green-top Guideline No. 52. May 2009.
